The study "Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy," published in Nature Medicine (2003), investigated benfotiamine, a lipid-soluble form of thiamine (vitamin B1), and its ability to prevent diabetic retinopathy by simultaneously inhibiting three harmful metabolic pathways activated by high blood sugar—the hexosamine, DAG-PKC,
